In patients with insulin resistance, the hyperinsulinemia may enhance the bioavailability of IGF-1 and IGF-2 by inhibiting the production of the IGFBP-1 and IGFBP-2 in the liver [46]. This evidence concerns the gene IGF1 and Hyperinsulinemia.